Browse CNOT11

Summary
SymbolCNOT11
NameCCR4-NOT transcription complex, subunit 11
Aliases C40; C2orf29; chromosome 2 open reading frame 29; UPF0760 protein C2orf29; CCR4-NOT transcription complex su ......
Chromosomal Location2q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus
Domain PF10155 Uncharacterized conserved protein (DUF2363)
Function

Component of the CCR4-NOT complex which is one of the major cellular mRNA deadenylases and is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation. Additional complex functions may be a consequence of its influence on mRNA expression. Is required for the association of CNOT10 with the CCR4-NOT complex. Seems not to be required for complex deadenylase function.

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000082 G1/S transition of mitotic cell cycle
GO:0000288 nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:0000289 nuclear-transcribed mRNA poly(A) tail shortening
GO:0000956 nuclear-transcribed mRNA catabolic process
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0006417 regulation of translation
GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest
GO:0007050 cell cycle arrest
GO:0007093 mitotic cell cycle checkpoint
GO:0007346 regulation of mitotic cell cycle
GO:0010608 posttranscriptional regulation of gene expression
GO:0010948 negative regulation of cell cycle process
GO:0016458 gene silencing
GO:0019439 aromatic compound catabolic process
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0031047 gene silencing by RNA
GO:0031570 DNA integrity checkpoint
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0034248 regulation of cellular amide metabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0042770 signal transduction in response to DNA damage
GO:0044270 cellular nitrogen compound catabolic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044783 G1 DNA damage checkpoint
GO:0044819 mitotic G1/S transition checkpoint
GO:0044843 cell cycle G1/S phase transition
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:0046700 heterocycle catabolic process
GO:0071156 regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0072331 signal transduction by p53 class mediator
GO:0072395 signal transduction involved in cell cycle checkpoint
GO:0072401 signal transduction involved in DNA integrity checkpoint
GO:0072413 signal transduction involved in mitotic cell cycle checkpoint
GO:0072422 signal transduction involved in DNA damage checkpoint
GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint
GO:0090068 positive regulation of cell cycle process
GO:1901361 organic cyclic compound catabolic process
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint
GO:1902402 signal transduction involved in mitotic DNA damage checkpoint
GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
Molecular Function -
Cellular Component GO:0030014 CCR4-NOT complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-429947: Deadenylation of mRNA
R-HSA-429914: Deadenylation-dependent mRNA decay
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804115: TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolCNOT11
NameCCR4-NOT transcription complex, subunit 11
Aliases C40; C2orf29; chromosome 2 open reading frame 29; UPF0760 protein C2orf29; CCR4-NOT transcription complex su ......
Chromosomal Location2q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CNOT11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCNOT11
NameCCR4-NOT transcription complex, subunit 11
Aliases C40; C2orf29; chromosome 2 open reading frame 29; UPF0760 protein C2orf29; CCR4-NOT transcription complex su ......
Chromosomal Location2q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CNOT11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.80; FDR: 0.03680 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCNOT11
NameCCR4-NOT transcription complex, subunit 11
Aliases C40; C2orf29; chromosome 2 open reading frame 29; UPF0760 protein C2orf29; CCR4-NOT transcription complex su ......
Chromosomal Location2q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CNOT11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0280.869
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.050.982
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0870.957
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0730.833
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0220.991
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1990.938
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0020.996
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0950.952
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0950.958
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0550.971
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1170.96
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1880.0124
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolCNOT11
NameCCR4-NOT transcription complex, subunit 11
Aliases C40; C2orf29; chromosome 2 open reading frame 29; UPF0760 protein C2orf29; CCR4-NOT transcription complex su ......
Chromosomal Location2q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CNOT11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCNOT11
NameCCR4-NOT transcription complex, subunit 11
Aliases C40; C2orf29; chromosome 2 open reading frame 29; UPF0760 protein C2orf29; CCR4-NOT transcription complex su ......
Chromosomal Location2q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CNOT11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CNOT11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCNOT11
NameCCR4-NOT transcription complex, subunit 11
Aliases C40; C2orf29; chromosome 2 open reading frame 29; UPF0760 protein C2orf29; CCR4-NOT transcription complex su ......
Chromosomal Location2q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CNOT11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCNOT11
NameCCR4-NOT transcription complex, subunit 11
Aliases C40; C2orf29; chromosome 2 open reading frame 29; UPF0760 protein C2orf29; CCR4-NOT transcription complex su ......
Chromosomal Location2q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CNOT11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCNOT11
NameCCR4-NOT transcription complex, subunit 11
Aliases C40; C2orf29; chromosome 2 open reading frame 29; UPF0760 protein C2orf29; CCR4-NOT transcription complex su ......
Chromosomal Location2q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CNOT11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCNOT11
NameCCR4-NOT transcription complex, subunit 11
Aliases C40; C2orf29; chromosome 2 open reading frame 29; UPF0760 protein C2orf29; CCR4-NOT transcription complex su ......
Chromosomal Location2q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CNOT11 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.